A Phase 1/2 interventional study of Yiyang Huoluo Decoction and conventional western medicine treatment in Coronary Heart Disease, Coronary Artery Disease and Atheroscleroses, sponsored by Xia Liang. Recruiting at 1 site in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Xia Liang · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.
Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 310th largest by planned enrollment of the 324 interventional ones that give a count, is one of 54 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 134 of the 209 other live ones, and was the 493rd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18–80
BrosMed Medical Co., Ltd · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in China, United States, Australia and 1 more country
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
543 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 24 · Phase 4 66
First in 2000; this study’s year is marked. 54 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 307 across the 324 interventional studies, 720 across the 218 observational. Of the 187 that completed or were terminated, 24 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 543 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xia Liang as lead sponsor.
Xia Liang has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
32 of the studies in Coronary Artery Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05175274Phase 3Qingdao Central HospitalColchicine Use for Primary Prevention of Coronary Artery Disease | 2027-03-01 |
| NCT07439133Phase 3Sinotau Pharmaceutical GroupComparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) | 2027-06 |
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT06845410Peking Union Medical College HospitalClinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study | 2026-12 |
| NCT06917664China National Center for Cardiovascular DiseasesTreatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease | 2026-12 |
Add all 32 to your calendar (.ics) → With an account.
Among the 543 studies in Coronary Artery Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if Yiyang Huoluo Decoction (a custom Chinese herbal medicine) works safely and effectively to treat coronary heart disease with atherosclerosis in older adults. It also aims to find out how this herbal treatment may affect blood vessel health and repair at a cellular level.
The main questions it aims to answer are:
Researchers will compare two groups of participants to see if the combined treatment works better than standard care alone.
Who can take part: Older adults diagnosed with coronary heart disease and atherosclerosis who meet the study's health and eligibility rules.
What participants will do:
All personal health information collected for this study will be kept private and confidential. Participation is completely voluntary, and participants may quit the study at any time for any reason without losing access to regular medical care.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
This study's planned enrollment of 30 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →This is the only study on the registry with Xia Liang as lead sponsor.
Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronary Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All of the following conditions must be met simultaneously for enrollment:
Exclusion Criteria:
Participants will be excluded if they meet any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
receive 12-week YH decoction treatment with 36-week conventional western medicine treatment: including antiplatelet drugs, statins, beta-blockers, and ACEI/ARB agents
Drug: Yiyang Huoluo Decoction · Drug: conventional western medicine treatment
only receive 36-week conventional western medicine treatment: including antiplatelet drugs, statins, beta-blockers, and ACEI/ARB agents
Drug: conventional western medicine treatment
The principal constituents of this decoction include Rehmanniae Radix (dried rehmannia root), Dioscoreae Rhizoma (Chinese yam rhizome), Cornus Officinalis Fructus (Asiatic dogwood fruit), Alismatis Rhizoma (water plantain rhizome), Poria Cocos (Indian bread), Moutan Cortex (moutan bark), Cinnamomi Ramulus (cinnamon twig), Astragali Radix (milk vetch root), Angelicae Sinensis Radix (Chinese angelica root), Pheretima (earthworm), Persicae Semen (peach seed), and Carthami Flos (safflower)
including antiplatelet drugs, statins, beta-blockers, and ACEI/ARB agents
TCM syndrome scores for chest discomfort due to yang qi deficiency and decline
TCM Syndrome Rating Scale for Chest Discomfort (Yang Qi Deficiency and Decline) (It includes 8 main symptoms, each scored 0-3, with a total score of 0-24. Higher scores represent more severe syndromes.)
Time frame: baseline, 12 weeks, and 36 weeks of treatment
CCS angina pectoris grade
Time frame: baseline, 12 weeks, 36 weeks of treatment
Incidence of in-stent restenosis
detected by coronary angiography
Time frame: 36-week of treatment
Changes in carotid intima-media thickness (IMT)
detected by carotid ultrasound
Time frame: baseline, 12 weeks, and 36 weeks of treatment
Total incidence of adverse events (AEs)
Time frame: during the 36-week treatment period
Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.